Vedolizumab for ulcerative colitis

ABSTRACT

An idiopathic, persistent inflammatory condition called ulcerative colitis affects the mucosa of the colon. Etiology of ulcerative colitis involves complex interactions between genetic susceptibility, environmental factors, and immune dysregulation. Vedolizumab is a humanized monoclonal antibody that blocks the gut-selective 47 integrin on the surface of certain leukocytes, preventing leukocyte trafficking to the digestive tract. Vedolizumab has been shown its effectiveness in the treatment of UC. This review covers the pathogenesis of ulcerative colitis as well as the pertinent therapeutic agents. It also covers the safety and efficacy of vedolizumab in terms of its molecular structure, physicochemical properties, mechanism of action, and comparison with other medications like infliximab, adalimumab, and tofacitinib used in the treatment of ulcerative colitis. It also offers other suggestions about the drug's potential in the future. Leukocytes that are surface-bound to the gut-selective 47